MDS Hub retweeted
🚨NEWS 🚨
First patient dosed in the phase II BEXMAB trial, evaluating bexmarilimab, an anti-Clever-1 humanized monoclonal antibody, in combination with standard of care in patients with R/R MDS previously treated with HMAs.
loom.ly/STJGPwE
#MedNews #leusm
MDS Hub retweeted
CONGRESS | #ASH23
Enrico Attardi @enrico_attardi @unitorvergata @StJude dissects ICC “diagnostic qualifiers”, using a cohort of 155 patients with #AML progressing from #MDS or MDS/MPN (sAML) and 65 patients with tAML, and comparing to 233 patients with de novo MDS-related AML (AML-TP53, AML with MDS-related gene mutations or cytogenetic abnormalities AML-TP53). ▪️91.7% of sAML cases were AML-MR by 2022 WHO, however ~80% fell into the ICC MDS-related profile with 11.1% not defined
▪️ELN 2022 stratified patients with tAML, but not sAML
▪️Estimated that 70% of sAML and >75% tAML could be captured through RT-PCR and conventional cytogenetics
▪️Proposes that tAML should be classified as a “second” neoplasm rather than sAML, and treatment decisions should be guided by genetic profile rather than antecedent diagnosis of MDS
@ASH_hematology #AMLsm #leusm
MDS Hub retweeted
CONGRESS | #ASH23
Eshana Shah @YaleMed presents a mixed methods approach to understanding individual-level social determinants of health (SDOH) in 52 patients with #AML, HR #MDS or #ALL, and explains that age (>65yrs), financial toxicity and lower health literacy, but not PHQ-4, contribute to missed clinic visits, and more ER and ICU visits. To address this, SDOH tools are needed to identify vulnerable patients, alongside provision of tailored education, improved caregiver engagement and community partnerships. @ASH_hematology #AMLsm #leusm #leukemia #MDSsm #ALLsm
MDS Hub retweeted
CONGRESS | #ASH23
Caspian Oliai @UCLAJCCC @UCLAHealth discusses ph1b trial of Orca-T. 1-yr RFS was similar between patients aged 18-55yrs (n=38) and those >55 yrs old (n=25); 1-yr NRM=0% in both groups; 1-yr OS=100% and 96%. Donor chimerism at 3mo >90% in all ages. 1 case of ≥Gr3 aGvHD in an older patient.
Summarizes that Orca-T is a well-tolerated alternative to conventional transplant and could improve outcomes in older patients. @ASH_hematology #AML #AMLsm #leusm #leukemia
MDS Hub retweeted
CONGRESS | #IACH23 | #CoMyDAL
Raphael Itzykson @raphaelitzykson @HopSaintLouis talks describes the need for a clear definition of MDS/AML. He describes therapeutic strategies including the benefit seen with CPX-351 in patients with MDS-type mutations and the potential of HMA+Ven.
@TheIACH #IACH2023 #AMLsm #MDSsm
MDS Hub retweeted
CONGRESS | #IACH23 | #CoMyDAL
Lisa Pleyer @CCSalzburg presents data showing the correlation between BM and PB VAF for the monitoring of myeloid neoplasm, even in the absence of circulating blasts or in neutropenia. She describes her strategy for using molecular data to guide treatment decisions in MDS and AML.
@TheIACH #IACH2023 #AMLsm #MDSsm
MDS Hub retweeted
Register to hear from experts:
🗣 @jjkiladjian
🗣 @AaronGerds
The webinar will include an in-depth discussion of a recent clinical trial of luspatercept and an interactive Q&A session.
loom.ly/JOBfpkk
#MPN #MPNsm #myelofibrosis #MF #CancerTreatment
MDS Hub retweeted
Congress | #EHA2023 | EHA-ISLH Laboratory Diagnosis Workshop
Robert Hasserjian, @MassGeneralNews provides an overview of the ICC for AML and MDS and a comparison with the WHO classification. They highlight that clinicians should be aware of both classifications. #leusm
MDS Hub retweeted
Congress | #EHA2023 | EHA-ISLH Laboratory Diagnosis Workshop
Michaela Fontenay, @univ_paris_cite, discusses the WHO classification of myeloid malignancies, with a particular focus on AML and MDS. The WHO classification is based on morphology, cytogenetics, and molecular features.
MDS Hub retweeted
CONGRESS| #ASCO23| Anthony Stein,@cityofhope reported preliminary results from the first in-human trial evaluating SAR443579 in pts with R/R AML, B-ALL or HR-MDS. Overall, it was well tolerated with no DLTs; CR/CRi was achieved in 18.8% at a dose of ≥ 1000 ug/kg/infusion
#ALLsm
MDS Hub retweeted
📊 Is tamibarotene combination therapy safe and effective in patients with RARA-positive AML?
Read our full visual abstract here 👉 loom.ly/JZqrd0o.
#AMLsm #leusm #leukemia
MDS Hub retweeted
CONGRESS | #ASH22
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRNA vaccinations and evaluates the promising future uses of mRNA technology.
MDS Hub retweeted
CONGRESS | #ASH22
@profshanecrotty from @ljiresearch discusses SARS-CoV-2 and data gathered to access immunological memory post COVID-19 vaccinations with the involvement of long lasting germinal centres to priming immunizations.
MDS Hub retweeted
Congress | #ASH22 @ColemanLindsley @DanaFarber gives a thought-provoking presentation on transplantation in pts with TP53-mutated MDS and AML. While outcomes are poor, allo-HSCT is associated with improved survival compared to not transplanting in pts with MDS. #leusm
MDS Hub retweeted
The cell surface antigen, CD43, as a novel and independent prognostic marker for patients with newly diagnosed multiple #myeloma: What do we know?
#mmsm
loom.ly/1JCPBbA
MDS Hub retweeted
👁️ A round-up of some exciting new developments in ocular #GvHD, from tear cytokine biomarkers to the effect of air humidity on the transplant ward. Read our summary article here 👇
@PKU1898 @jointmedi @UniCologne
loom.ly/EugfFI4
MDS Hub retweeted
Did you miss our MPN Hub FREE WEBINAR: Clinical trial club | Novel agents for the treatment of advanced myelofibrosis? The session is now available!
View here: mpn-hub.com/medical-informat…
Please share any feedback you have in the comments!
#mpnsm
MDS Hub retweeted
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. eviden.cc/3BYpDep
#MDS #LeuSM #CMML































































